MedPath

Open-Label Extension Study to Assess the Safety and Seizure Frequency Associated With Lacosamide for Primary Generalized Tonic-Clonic Seizures in Subjects With Epilepsy

Phase 2
Completed
Conditions
Epilepsy
Interventions
Registration Number
NCT01118962
Lead Sponsor
UCB BIOSCIENCES, Inc.
Brief Summary

The purpose is to obtain data on the safety and seizure frequency associated with long-term oral Lacosamide for uncontrolled primary generalized tonic-clonic (PGTC) seizures in subjects with idiopathic generalized Epilepsy. Additionally, to allow subjects who have completed SP0961 (NCT01118949) to continue to receive Lacosamide.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
39
Inclusion Criteria
  • Subject completed the SP0961 (NCT01118949) study
  • Subject is expected to benefit from participation in an open-label extension study with Lacosamide, in the opinion of the investigator
Exclusion Criteria
  • Subject meets the withdrawal criteria for SP0961 (NCT01118949) or is experiencing an ongoing Serious Adverse Event (SAE)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
LacosamideLacosamideLacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses.
Primary Outcome Measures
NameTimeMethod
Number of Participants With Treatment-emergent Adverse Events (TEAEs) From Visit 1 to the End of Study (Approximately 61 Weeks)From Visit 1 to the end of study (Approximately 61 weeks)
Number of Participants Withdrawn From the Study Due to Treatment-emergent Adverse Events (TEAEs) From Visit 1 to the End of Study (Approximately 61 Weeks)From Visit 1 to the end of study (Approximately 61 weeks)
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (19)

609

🇺🇸

Bethesda, Maryland, United States

601

🇺🇸

Nashville, Tennessee, United States

605

🇺🇸

Lexington, Kentucky, United States

603

🇺🇸

Phoenix, Arizona, United States

628

🇺🇸

Aurora, Colorado, United States

607

🇺🇸

New York, New York, United States

616

🇺🇸

Louisville, Kentucky, United States

623

🇺🇸

Renton, Washington, United States

624

🇺🇸

Madison, Wisconsin, United States

610

🇺🇸

Norfolk, Virginia, United States

613

🇺🇸

Atlanta, Georgia, United States

617

🇺🇸

Boise, Idaho, United States

614

🇺🇸

Fort Wayne, Indiana, United States

619

🇺🇸

Scarborough, Maine, United States

612

🇺🇸

Dallas, Texas, United States

615

🇺🇸

Chesterfield, Missouri, United States

620

🇺🇸

Columbus, Ohio, United States

602

🇺🇸

Little Rock, Arkansas, United States

608

🇺🇸

Charleston, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath